Home > Offer to Sell > Intermediates > Pharmaceutical intermediates > Pirfenidone CAS 53179-13-8 (jerryzhang001@chembj.com)
Pirfenidone CAS 53179-13-8 (jerryzhang001@chembj.com)
Inquiry
| Post Date: | Apr 20,2017 |
| Expiry Date: | Apr 20,2018 |
| Detailed Description: |
Cas No. :53179-13-8
Payment Method: T/T; Western Union; Moneygram and Bitcoin Pirfenidone CAS 53179-13-8 Product Name: Pirfenidone; Synonyms: 5-methyl-1-phenyl-2(1h)-pyridon;amr-69;PIRFENIDONE;5-METHYL-1-PHENYL-1H-PYRIDIN-2-ONE;5-METHYL-1-PHENYL-2(1H)-PYRIDINONE;5-METHYL-1-PHENYL-2-(1H)-PYRIDONE;5-Methyl-N-phenyl-2-1H-pyridone;Pirfenidone also see 5-Methyl-1-Phenyl-2(1H)-Pyridinone; CAS: 53179-13-8; MF: C12H11NO; MW: 185.22; Product Categories: Aromatics Compounds;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Cytokine signaling;Inhibitors; Melting point: 96-97°C; storage temp.: Store at RT; Description: Pirfenidone (PFD) is a novel kind of pyridine ketones which has a broad-spectrum anti-fibrotic effect, being able to prevent and reverse the formation of fibrosis and scar. It entered into market in Shionogi, Japan in 2008 and has been approved by the US food and Drug Administration. It is the first drug which has gone through phase III clinical trials (including repeating, randomized, and placebo-control) which has demonstrates its effectiveness in treating idiopathic pulmonary fibrosis (IPF); moreover, the drug has relative good efficacy in treating some fibrotic diseases such as renal interstitial fibrosis and liver fibrosis. Furthermore, it is also widely applied in the phase II clinical study in kidney disease (focal segmental glomerulosclerosis), hypertrophic cardiomyopathy, adult type I neurofibromatosis, youth I type of neurofibromatosis and plexiform neurofibromas, diabetes together with kidney disease. Clinical application: 1. Idiopathic pulmonary fibrosis degeneration Idiopathic pulmonary fibrosis (IPF) is an unexplained, poor prognosis and high-mortality chronic inflammatory interstitial lung disease. At the same time, PFD is an anti-inflammatory, anti-fibrotic agent which can be used for the treatment of IPF. 2. Liver Fibrosis 3. Renal fibrosis disease 4. Multiple Sclerosis Multiple sclerosis (MS) is a central nervous system-related and the immune-related inflammation and demyelinating diseases. Immune factors relating to it are activation of stellate cells, glial cell, and endothelial cell and the increase of lymphocytes, while PDF have effects of inhibiting the cell activation. 5. Myocardial fibrosis Cardiovascular diseases such as hypertension, cardiomyopathy, and atrial fibrillation can all lead to myocardial fibrosis, thereby resulting in the disease progression or development. Using PDF for treatment of cardiomyopathy caused by Duchenne muscular dystrophy can inhibit myocardial fibrosis, improve the cardiac function. PFD can reduce the incidence of atrial fibrillation and myocardial remodeling through inhibiting fibrosis. 6. Neoplastic diseases: neurofibroma, leiomyoma, and malignant gliomas. 7. Prevention of fibrosis after the organ transplant. 8. Rheumatoid arthritis. |
| CAS Registry Number: | 53179-13-8 |
| Synonyms: | ;5-Methyl-1-phenyl-2-(1H)-pyridone;5-methyl-1-phenylpyridin-2(1H)-one; |
| Molecular Formula: | C12H11NO |
| Molecular Weight: | 185.2218 |
| Molecular Structure: | 
|
| Hazard Symbols: |  Xn:Harmful; |
| Risk Codes: | R22:; |
| Safety Description: | S36:; |
| Company: | Nanjing Bangnuo Biotechnology Co., Ltd. [ China ] |
| Contact: | Jerry Zhang |
| Tel: | 86-25-52198306 |
| Fax: | |
| Email: | jerryzhang001@chembj.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
